Amir Hefni, Resolution Therapeutics CEO
Resolution raises $85M to test macrophage therapies in end-stage liver disease
By the end of the year, a British biotech plans to start testing a new kind of cell therapy based on macrophages, a roaming immune …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
